Search results for "Author's View"

showing 3 items of 13 documents

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies

2015

We have developed a highly versatile platform for the systematic retrieval of T-cell receptors (TCRs) from single-antigen-reactive T cells and for characterization of their function and specificity. This approach enables rapid extraction of multiple TCRs from repertoires in individuals and not only broadens the diversity of TCRs suitable for clinical use, but also sets the stage for actively personalized immunotherapeutic strategies.

epitopeAdoptive cell transferImmunologyT-cell receptorhemic and immune systemschemical and pharmacologic phenomenaComputational biologyBiologypersonalized immunotherapybiological factorsEpitopeOncologyAntigen specificImmunologyImmunology and AllergyT cell engineeringT cell receptorAuthor's Viewtissuesadoptive cell transferOncoImmunology
researchProduct

Targeting the tumor mutanome for personalized vaccination therapy

2012

Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source for effective vaccines.

next generation sequencingSomatic cellbusiness.industryImmunologyBioinformaticscancer immunogenicityDNA sequencingEpitopeVaccinationOncologyImmunizationIn vivoImmunogenic tumornon-synonymous mutationsCancer researchindividualized therapyImmunology and AllergyMedicinetumor mutationsB16f10 melanomacancer vaccinationbusinessAuthor's ViewOncoImmunology
researchProduct

Interferon α interferes with immunological tolerance.

2013

The ability of regulatory T cells (Tregs) to promote immunological tolerance represents an important obstacle in cancer immunotherapy. We have recently discovered that the clinically established immunotherapeutic agent interferon α (IFNα) inactivates the suppressive functions of human Tregs. Here, we outline the mechanisms whereby IFNα mediates this important function and discuss its therapeutic implications for cancer immunotherapy.

tolerancebusiness.industrymedicine.medical_treatmentImmunologyImmunotherapeutic agentCancerNK cellsmedicine.diseasePDEregulatory T cellsIfn alphaOncologyCancer immunotherapyInterferon αcAMPImmunologymedicineImmunology and AllergycancerIFN-alphabusinessAuthor's ViewFunction (biology)Oncoimmunology
researchProduct